Home The Word Brain My Amedeo FAQ Privacy About   


Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts

This week, 27 April 2025:

  1. Treatment-resistant hypertension
  2. Influenza transmission
  3. Nanoplastics in human brains
  4. Malaria elimination
  5. Chikungunya vaccine

  Cervical Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 145 articles:
HTML format



Single Articles


    January 2025
  1. DE FOUW M, Boere MWM, Nakisige C, Nabwire M, et al
    Cervical cancer care at a tertiary oncology facility in Uganda: Comparing daily practice with national treatment targets on cervical cancer control.
    PLoS One. 2025;20:e0316323.
    PubMed     Abstract available


  2. TAKAHASHI Y, Sasamori Y, Higuchi R, Kaku A, et al
    Effects of different educational interventions on cervical cancer knowledge and human papillomavirus vaccination uptake among young women in Japan: Preliminary results of a cluster randomized controlled trial.
    PLoS One. 2025;20:e0311588.
    PubMed     Abstract available


  3. KHOMPHAIBOONKIJ U, Sreamsukcharoenchai N, Pitakkarnkul S, Rittiluechai K, et al
    Correction: Knowledge of Thai women in cervical cancer etiology and screening.
    PLoS One. 2025;20:e0318184.
    PubMed     Abstract available


  4. ASIRWA FC, Bresnahan BW, Yego F, Duncan D, et al
    A prospective model of the potential clinical and economic impact of cervical cancer screening supported by a mobile phone app.
    PLoS One. 2025;20:e0316001.
    PubMed     Abstract available


  5. DEMEKE AD, Deribe B, Girma M, Gizaw M, et al
    Screening attendance of breast or cervical cancers and its associated factors among 30-49 year old women in Gedeo zone, South Ethiopia: Cross-sectional study.
    PLoS One. 2025;20:e0315891.
    PubMed     Abstract available


  6. UM S, Sopheab H
    Breast and cervical cancer screening among women at reproductive age in Cambodia: A secondary analysis of Cambodia Demographic and Health Survey 2022.
    PLoS One. 2025;20:e0295881.
    PubMed     Abstract available



  7. Retraction: Long Noncoding RNA-EBIC Promotes Tumor Cell Invasion by Binding to EZH2 and Repressing E-Cadherin in Cervical Cancer.
    PLoS One. 2025;20:e0318789.
    PubMed    


  8. OPITO R, Tiyo Ayikobua E, Akurut H, Alwedo S, et al
    Factors associated with uptake and acceptability of cervical cancer screening among female sex workers in Northeastern Uganda: A cross-sectional study.
    PLoS One. 2025;20:e0312988.
    PubMed     Abstract available


  9. GAO Y, Liang G, Chang C, Pan F, et al
    Analysis of cervical and breast cancer screening behavior and its influencing factors among urban and rural women in Beijing.
    PLoS One. 2025;20:e0316898.
    PubMed     Abstract available


  10. WAGNER GJ, Bogart LM, Matovu JKB, Gwokyalya V, et al
    Study protocol for a hybrid implementation-effectiveness trial of Game Changers for Cervical Cancer Prevention in Uganda.
    PLoS One. 2025;20:e0317491.
    PubMed     Abstract available


  11. PANERU B, Karmacharya A, Bharati A, Makaju S, et al
    Correction: Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal.
    PLoS One. 2025;20:e0318367.
    PubMed     Abstract available


  12. AYTAC S, Ozbey G
    Photodiagnosis and photodynamic recognition of cervical cancer with SEM and AFM images.
    PLoS One. 2025;20:e0316544.
    PubMed     Abstract available


  13. HAMZA MN, Tariqul Islam M, Lavadiya S, Ud Din I, et al
    Design and validation of ultra-compact metamaterial-based biosensor for non-invasive cervical cancer diagnosis in terahertz regime.
    PLoS One. 2025;20:e0311431.
    PubMed     Abstract available


  14. MALOBA M, Finocchario-Kessler S, Wexler C, Staggs V, et al
    The Cancer Tracking System (CATSystem): Study protocol of a randomized control trial to evaluate a systems level intervention for cervical cancer screening, treatment, referral and follow up in Kenya.
    PLoS One. 2025;20:e0318941.
    PubMed     Abstract available


  15. REMMEL ML, Suija K, Markina A, Tisler A, et al
    Navigating the risks: Stakeholder views on risk-based cervical cancer screening.
    PLoS One. 2025;20:e0317986.
    PubMed     Abstract available


  16. ASIIMWE S, Bagenda FN, Mugisa T
    Factors associated with uptake of human papilloma virus vaccine among adolescent girls: A cross sectional survey on insights into HPV Infection Prevention in Kabarole District, Western Uganda.
    PLoS One. 2025;20:e0306960.
    PubMed     Abstract available


  17. ETEMADIFAR M, Shoeib S, Salari M, Etemadifar M, et al
    Gynecologic health of women with multiple sclerosis: An overview on the current status and findings of Pap tests in a low-income setting.
    PLoS One. 2025;20:e0320069.
    PubMed     Abstract available


  18. KIDAYA BN, Mwanga JR, Muhini OO, Mwaisungu HM, et al
    Healthcare-seeking behaviors and factors influencing non-adherence among cervical cancer patients attending Bugando Oncology Clinic in Mwanza, Tanzania: A qualitative Phenomenological study.
    PLoS One. 2025;20:e0317609.
    PubMed     Abstract available


  19. XIE R, Xie K, Lin X, Ji Y, et al
    A Comparison of neoadjuvant chemotherapy and concurrent chemoradiotherapy for for FIGO 2018 stage IB3/IIA2 Cervical squamous cell carcinoma: Long-term efficacy and safety in a resource-limited setting.
    PLoS One. 2025;20:e0319405.
    PubMed     Abstract available


  20. BURKE-GARCIA A, Cutroneo E, Afanaseva D, Madden K, et al
    Findings from a qualitative analysis: Social media influencers of color as trusted messengers of HPV vaccination messages.
    PLoS One. 2025;20:e0319160.
    PubMed     Abstract available


  21. MAFI S, Theuillon F, Meyer S, Woillard JB, et al
    Comparative evaluation of Allplex HPV28 and Anyplex II HPV28 assays for high-risk HPV genotyping in cervical samples.
    PLoS One. 2025;20:e0320978.
    PubMed     Abstract available


  22. AVILA E, Hernandez-Monterde LD, Cedro-Tanda A, Lizardi-Aguilera TM, et al
    Transcriptomic profile induced by calcitriol in CaSki human cervical cancer cell line.
    PLoS One. 2025;20:e0319812.
    PubMed     Abstract available


  23. WANG G, Jia C, Wang D, Liang L, et al
    Scutellaria Barbata inhibits epithelial-mesenchymal transformation through PI3K/AKT and MDM2 thus inhibiting the proliferation, migration and promoting apoptosis of Cervical Cancer cells.
    PLoS One. 2025;20:e0321556.
    PubMed     Abstract available


  24. ABATE A, Munshea A, Nibret E, Bezabih B, et al
    Evaluation of Onco E6 point of care rapid diagnostic test for human papilloma virus in Bahir Dar, Amhara Regional State, Ethiopia.
    PLoS One. 2025;20:e0321076.
    PubMed     Abstract available


  25. BAASLAND I, Bjorge T, Engesaeter B, Trope A, et al
    Cervical intraepithelial neoplasia grade 1 and long-term risk of progression and treatment.
    PLoS One. 2025;20:e0320739.
    PubMed     Abstract available


  26. MELAKU A, Abebe SN, Haile S
    Utilization of screening services on cervical cancer and associated factors among female health workers in Addis Ababa, Ethiopia.
    PLoS One. 2025;20:e0321662.
    PubMed     Abstract available


    January 2024
  27. ALJREES T
    Improving prediction of cervical cancer using KNN imputer and multi-model ensemble learning.
    PLoS One. 2024;19:e0295632.
    PubMed     Abstract available


  28. MUNSHI RM
    Novel ensemble learning approach with SVM-imputed ADASYN features for enhanced cervical cancer prediction.
    PLoS One. 2024;19:e0296107.
    PubMed     Abstract available


  29. YU C, Wu X, Zhang S, Zhang L, et al
    Prognostic model for survival in patients with neuroendocrine carcinomas of the cervix: SEER database analysis and a single-center retrospective study.
    PLoS One. 2024;19:e0296446.
    PubMed     Abstract available


  30. GUILLAUME D, Waheed DE, Schleiff M, Muralidharan KK, et al
    Global perspectives of determinants influencing HPV vaccine introduction and scale-up in low- and middle-income countries.
    PLoS One. 2024;19:e0291990.
    PubMed     Abstract available


  31. SARMIENTO-MEDINA MI, de Amaya MP, Villamizar-Gomez L, Gonzalez-Coba AC, et al
    High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study.
    PLoS One. 2024;19:e0297579.
    PubMed     Abstract available


  32. KANG SW, Kang OJ, Lee JY, Kim H, et al
    Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6/E7 combined with cisplatin in a xenograft model of cervical cancer.
    PLoS One. 2024;19:e0298815.
    PubMed     Abstract available


  33. MANGENAH C, Sibanda EL, Maringwa G, Sithole J, et al
    Provider and female client economic costs of integrated sexual and reproductive health and HIV services in Zimbabwe.
    PLoS One. 2024;19:e0291082.
    PubMed     Abstract available


  34. MUNSHI RM
    Correction: Novel ensemble learning approach with SVM-imputed ADASYN features for enhanced cervical cancer prediction.
    PLoS One. 2024;19:e0298980.
    PubMed     Abstract available


  35. VARON ML, Geng Y, Fellman BM, Troisi C, et al
    Interventions to increase follow-up of abnormal cervical cancer screening results: A systematic literature review and meta-analysis.
    PLoS One. 2024;19:e0291931.
    PubMed     Abstract available


  36. YAO B, Peng J, Song W, Yang L, et al
    Real-world effectiveness of cytology and HPV-based screening strategy in cervical cancer screening: A cross-sectional population-based study in Chengdu, China.
    PLoS One. 2024;19:e0299651.
    PubMed     Abstract available


  37. SUN J, Frick KD, Liang H, Chow CM, et al
    Examining cancer screening disparities by race/ethnicity and insurance groups: A comparison of 2008 and 2018 National Health Interview Survey (NHIS) data in the United States.
    PLoS One. 2024;19:e0290105.
    PubMed     Abstract available


  38. ZHANG J, Yuan J, Zhang D, Yang Y, et al
    Short video platforms as sources of health information about cervical cancer: A content and quality analysis.
    PLoS One. 2024;19:e0300180.
    PubMed     Abstract available


  39. CAROZZI FM, Royder Yanez R, Paganini I, Sani C, et al
    Cervical cancer prevention: Feasibility of self-sampling and HPV testing in rural and urban areas of Bolivia: An observational study.
    PLoS One. 2024;19:e0292605.
    PubMed     Abstract available


  40. LIU Z, Fan T, Mo X, Kan J, et al
    Association between multiple sclerosis and cancer risk: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0298271.
    PubMed     Abstract available


  41. LIN Y, Long Y, He J, Yi Q, et al
    The residual rate of HPV and the recurrence rate of CIN after LEEP with negative margins: A meta-analysis.
    PLoS One. 2024;19:e0298520.
    PubMed     Abstract available


  42. OOMMEN AM, Isaac R, Paul B, Weller D, et al
    Strategies for primary HPV test-based cervical cancer screening programme in resource-limited settings in India: Results from a quasi-experimental pragmatic implementation trial.
    PLoS One. 2024;19:e0301385.
    PubMed     Abstract available


  43. LEMLEM SB, Gary RA, Yeager KA, Sisay MM, et al
    Psychometric properties of a modified health belief model for cervical cancer and visual inspection with acetic acid among healthcare professionals in Ethiopia.
    PLoS One. 2024;19:e0295905.
    PubMed     Abstract available


  44. KHUMALO PG, Carey M, Mackenzie L, Sanson-Fisher R, et al
    Cervical cancer screening knowledge and associated factors among Eswatini women: A cross-sectional study.
    PLoS One. 2024;19:e0300763.
    PubMed     Abstract available


  45. DUA R, Bhardwaj T, Ahmad I, Somvanshi P, et al
    Investigating the potential of Juglans regia phytoconstituents for the treatment of cervical cancer utilizing network biology and molecular docking approach.
    PLoS One. 2024;19:e0287864.
    PubMed     Abstract available


  46. ZEBER-LUBECKA N, Kulecka M, Dabrowska M, Baginska-Drabiuk K, et al
    Cervical microbiota dysbiosis associated with high-risk Human Papillomavirus infection.
    PLoS One. 2024;19:e0302270.
    PubMed     Abstract available


  47. XU F, Carlson SA, Greenlund KJ
    Understanding primary care providers' attitudes towards preventive screenings to patients with inflammatory bowel disease.
    PLoS One. 2024;19:e0299890.
    PubMed     Abstract available


  48. MOSHI JM, Ummelen M, Smedts F, Ramaekers FCS, et al
    Inhibition of cytosine 5-hydroxymethylation during progression of cancer precursor lesions in the uterine cervix.
    PLoS One. 2024;19:e0297008.
    PubMed     Abstract available


  49. TIRKASO BH, Bayisa TH, Desta TW
    Histopathologic patterns and factors associated with cervical lesions at Jimma Medical Center, Jimma, Southwest Ethiopia: A two-year cross-sectional study.
    PLoS One. 2024;19:e0301559.
    PubMed     Abstract available


  50. WANG QL, Gong C, Meng XY, Fu M, et al
    TPP1 is associated with risk of advanced precursors and cervical cancer survival.
    PLoS One. 2024;19:e0298118.
    PubMed     Abstract available


  51. SHIMELS T, Gashawbeza B, Fenta TG
    Validation of the Amharic version of perceived access to healthcare services for patients with cervical cancer in Ethiopia: A second-order confirmatory factor analysis.
    PLoS One. 2024;19:e0300815.
    PubMed     Abstract available


  52. ILIKA CP, Eleje GU, Chiemeka ME, Ilika FN, et al
    Effects of speculum lubrication on cervical smears for cervical cancer screening: A double blind randomized clinical trial.
    PLoS One. 2024;19:e0292207.
    PubMed     Abstract available


  53. BROSHKEVITCH CJ, Barnabas RV, Liu G, Palanee-Phillips T, et al
    Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis.
    PLoS One. 2024;19:e0301997.
    PubMed     Abstract available


  54. HUSSEIN K, Kokwaro G, Wafula F, Kassie GM, et al
    Assessing the influence of the health system on access to cervical cancer prevention, screening, and treatment services at public health centers in Addis Ababa, Ethiopia.
    PLoS One. 2024;19:e0300152.
    PubMed     Abstract available


  55. AGYARE GYANE F, Modey E, Maya E, Bonney EY, et al
    Prevalence and risk factors associated with high-risk human papillomavirus infection among women living with HIV (WLWH) at a tertiary health facility in Accra, Ghana.
    PLoS One. 2024;19:e0303535.
    PubMed     Abstract available


  56. KIM JY, Jung JH, Jung S, Lee S, et al
    Glyoxalase 1: Emerging biomarker and therapeutic target in cervical cancer progression.
    PLoS One. 2024;19:e0299345.
    PubMed     Abstract available


  57. WANG Q, Xu M, Zhou H, Li Y, et al
    Prevalence characteristics of cervical human papillomavirus infection in Chengdu and Aba District, Sichuan Province, China.
    PLoS One. 2024;19:e0304760.
    PubMed     Abstract available


  58. TONG Y, Jia L, Li M, Li H, et al
    Identification of exosomal circSLC26A4 as a liquid biopsy marker for cervical cancer.
    PLoS One. 2024;19:e0305050.
    PubMed     Abstract available


  59. TSIMA BM, Motlhatlhedi K, Sharma K, Rantshabeng P, et al
    The association between smoking and cervical human papillomavirus infection among women from indigenous communities in western Botswana.
    PLoS One. 2024;19:e0302153.
    PubMed     Abstract available


  60. NONBOE MH, Napolitano GM, Kann C, Andersen B, et al
    Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study.
    PLoS One. 2024;19:e0306044.
    PubMed     Abstract available


  61. GONG S, Li G, Li D, Liu Y, et al
    The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases.
    PLoS One. 2024;19:e0305670.
    PubMed     Abstract available


  62. QI J, Li J, Zhu X, Zhao S, et al
    Endothelial cell specific molecule 1 promotes epithelial-mesenchymal transition of cervical cancer via the E-box binding homeobox 1.
    PLoS One. 2024;19:e0304597.
    PubMed     Abstract available


  63. JIN S, Lin F, Yang L, Zhang Q, et al
    Association between dietary folate intake and HPV infection: NHANES 2005-2016.
    PLoS One. 2024;19:e0306636.
    PubMed     Abstract available


  64. CASTELLANO T, ElHabr AK, Washington C, Ting J, et al
    Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.
    PLoS One. 2024;19:e0307282.
    PubMed     Abstract available


  65. BALQIS-ALI NZ, Anis-Syakira J, Fun WH, Mohd Said Z, et al
    Achieving cervical cancer elimination: The simulated impacts of HPV vaccination and transitioning from liquid-based cytology to HPV-based screening test.
    PLoS One. 2024;19:e0307880.
    PubMed     Abstract available



  66. Retraction: Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis.
    PLoS One. 2024;19:e0308113.
    PubMed    


  67. MUCHAILI L, Simushi P, Mweene BC, Mwakyoma T, et al
    Prevalence and correlates of Human Papillomavirus infection in females from Southern Province, Zambia: A cross-sectional study.
    PLoS One. 2024;19:e0299963.
    PubMed     Abstract available


  68. LORDELO MV, Oliveira CZ, Aguirre Buexm L, Vieira Reis RM, et al
    Randomized experimental population-based study to evaluate the acceptance and completion of and preferences for cervical cancer screening.
    PLoS One. 2024;19:e0306130.
    PubMed     Abstract available


  69. NAZRUL N, de Fouw M, Beltman JJ, de Zeeuw J, et al
    Understanding cervical cancer awareness in hard-to-reach areas of Bangladesh: A cross-sectional study involving women and household decisionmakers.
    PLoS One. 2024;19:e0304396.
    PubMed     Abstract available


  70. GOLALIPOUR A, Mohammadi A, Hosseinzadeh S, Soltani A, et al
    Synergistic cytotoxicity of olive leaf extract-loaded lipid nanocarriers combined with Newcastle disease virus against cervical cancer cells.
    PLoS One. 2024;19:e0308599.
    PubMed     Abstract available


  71. HARIPRASAD R, Bagepally BS, Kumar S, Pradhan S, et al
    Cost-utility analysis of primary HPV testing through home-based self-sampling in comparison to visual inspection using acetic acid for cervical cancer screening in East district, Sikkim, India, 2023.
    PLoS One. 2024;19:e0300556.
    PubMed     Abstract available


  72. GOMES FC, Galhardo DDR, Navegante ACG, Santos GSD, et al
    Bioinformatics analysis to identify the relationship between human papillomavirus-associated cervical cancer, toll-like receptors and exomes: A genetic epidemiology study.
    PLoS One. 2024;19:e0305760.
    PubMed     Abstract available


  73. ROMLI R, Mohamad EMW, Abd Rahman R, Chew KT, et al
    Validation and usability of SeDAR e-health video for enhancing cervical cancer screening.
    PLoS One. 2024;19:e0310555.
    PubMed     Abstract available


  74. ROBLEDO-CADENA DX, Pacheco-Velazquez SC, Vargas-Navarro JL, Padilla-Flores JA, et al
    Synergistic celecoxib and dimethyl-celecoxib combinations block cervix cancer growth through multiple mechanisms.
    PLoS One. 2024;19:e0308233.
    PubMed     Abstract available


  75. DANTAS DM, de Souza ATB, de Araujo Santos Camargo JD, Costa APF, et al
    Efficacy and safety of pembrolizumab in cervical cancer: Protocol for systematic review and meta-analysis of randomized clinical trials.
    PLoS One. 2024;19:e0312004.
    PubMed     Abstract available


  76. TWABI HH, Msosa TC, Meja SJ, Mukoka M, et al
    Spatial distribution and characteristics of women reporting cervical cancer screening in Malawi: An analysis of the 2020 to 2021 Malawi Population-based HIV Impact Assessment survey data.
    PLoS One. 2024;19:e0309053.
    PubMed     Abstract available


  77. SUTHERLAND EK, Smith JD, Ofori-Boateng M, Kushitor SB, et al
    Study protocol for the development of a real-time interface showing the availability of breast and cervical cancer services in Ghana.
    PLoS One. 2024;19:e0312150.
    PubMed     Abstract available


  78. RONG Y, Yang Y, Zhang X, Zhou X, et al
    Pain scores reduction with the use of ultrasound-guided paracervical nerve block in patients with cervical cancer undergoing intracavitary brachytherapy: A randomized controlled trial.
    PLoS One. 2024;19:e0310238.
    PubMed     Abstract available


  79. SULTANOV M, Koot JAR, de Bock GH, Greuter MJW, et al
    High-risk human papillomavirus testing for cervical cancer screening in Uganda: Considering potential harms and benefits in a low-resource setting.
    PLoS One. 2024;19:e0312295.
    PubMed     Abstract available


  80. LAHOLE BK, Woldamlak M, Kussia W
    Determinants of cervical cancer screening intention among reproductive age women in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0312449.
    PubMed     Abstract available


  81. ILIC I, Babic G, Dimitrijevic A, Grujicic SS, et al
    Detecting the impact of diagnostic procedures in Pap-positive women on anxiety using artificial neural networks.
    PLoS One. 2024;19:e0312870.
    PubMed     Abstract available


  82. BIRARA M, Urgie T, Sium AF
    Locally advanced cervical cancer: Neoadjuvant chemotherapy plus radical surgery an alternative approach to chemo-radiation in a low-income setting: A descriptive study.
    PLoS One. 2024;19:e0310457.
    PubMed     Abstract available


  83. CAMPUZANO TMF, Borba MACSM, de Mendonca Batista P, Nadalin M, et al
    Real world data on cervical cancer treatment patterns, healthcare access and resource utilization in the Brazilian public healthcare system.
    PLoS One. 2024;19:e0312757.
    PubMed     Abstract available


  84. AREVALOS A, Valenzuela A, Mongelos P, Barrios H, et al
    Genital infections in high-risk human papillomavirus positive Paraguayan women aged 30-64 with and without cervical lesions.
    PLoS One. 2024;19:e0312947.
    PubMed     Abstract available


  85. BAWALLE AA, Nguyen TXT, Khan MSR, Kadoya Y, et al
    Impact of financial literacy and education on breast and cervical cancer screening participation in Japan.
    PLoS One. 2024;19:e0313687.
    PubMed     Abstract available


  86. PLISKO O, Zodzika J, Jermakova I, Pcolkina K, et al
    Prediction of high-grade cervical precancerous abnormalities: The role of personal factors, vaginal microflora, sexually transmitted infections, and high-risk human papillomavirus.
    PLoS One. 2024;19:e0313004.
    PubMed     Abstract available


  87. ABDULL RAHIM U, Mustapa M, Mohamed Shakrin NNS, Nurdin A, et al
    Current evidence and future direction on evaluating the anticancer effects of curcumin, gingerols, and shogaols in cervical cancer: A systematic review.
    PLoS One. 2024;19:e0314280.
    PubMed     Abstract available


  88. DANIELS V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, et al
    Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia.
    PLoS One. 2024;19:e0310591.
    PubMed     Abstract available


  89. OWARE J, Iddrisu M, Konlan KD, Dzansi G, et al
    Personal and workplace factors influencing the resilience of nurses caring for women with cervical cancer in a resource-constrained setting in Ghana.
    PLoS One. 2024;19:e0314764.
    PubMed     Abstract available


  90. WANG J, Lu Y, Li F, Yao D, et al
    Preserving circumflex iliac lymph nodes to reduce the incidence of lower limb lymphedema following lymphadenectomy in cervical and endometrial cancers: A prospective randomized controlled trial.
    PLoS One. 2024;19:e0311144.
    PubMed     Abstract available


  91. ASGEDOM YS, Hailegebireal AH, Woldegeorgis BZ, Koyira MM, et al
    Towards 90-70-90 targets: Individual and community level factors associated with cervical cancer screening among women of reproductive age in Tanzania: A multi-level analysis based on 2022 Tanzania demographic and health survey.
    PLoS One. 2024;19:e0315438.
    PubMed     Abstract available


  92. CHAKRABORTY S, Nessa A, Ferdous NE, Rahman MM, et al
    Prevalence and genotypic distribution of high-risk human papillomavirus (HPV) among ever-married women in coastal regions of Bangladesh.
    PLoS One. 2024;19:e0313396.
    PubMed     Abstract available


  93. LIM C, Seo YJ, Lee JY, Jung ES, et al
    Evaluation of the cervical liquid-based cytology sample as a microbiome resource for dual diagnosis.
    PLoS One. 2024;19:e0308985.
    PubMed     Abstract available


  94. CAO Q, Hou Y, Wang C, Yin J, et al
    Effect of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0312128.
    PubMed     Abstract available


  95. BHENGU P, Ndwandwe D, Cooper S, Katoto PDMC, et al
    Behavioural and social drivers of human papillomavirus vaccination in eThekwini District of KwaZulu-Natal Province, South Africa.
    PLoS One. 2024;19:e0311509.
    PubMed     Abstract available


  96. OHYA A, Miyamoto T, Ichinohe F, Kobara H, et al
    Problems of magnetic resonance diagnosis for gastric-type mucin-positive cervical lesions of the uterus and its solutions using artificial intelligence.
    PLoS One. 2024;19:e0315862.
    PubMed     Abstract available


    January 2023
  97. RODRIGUEZ NM, Brennan LP, Claure L, Balian LN, et al
    Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection.
    PLoS One. 2023;18:e0282853.
    PubMed     Abstract available


  98. YAN L, Xiao X, He L, Shi L, et al
    Efficacy of optical coherence tomography in the triage of women with minor abnormal cervical cytology before colposcopy.
    PLoS One. 2023;18:e0282833.
    PubMed     Abstract available


  99. CHOI J, Markham C, Tami-Maury I, Kim S, et al
    Maternal perceptions of vaccinating boys against human papillomavirus (HPV) in Seoul, South Korea: A descriptive exploratory qualitative study.
    PLoS One. 2023;18:e0282811.
    PubMed     Abstract available


  100. GIBSON-HELM M, Slater T, MacDonald EJ, Stevenson K, et al
    Te Ara Waiora-Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial.
    PLoS One. 2023;18:e0280643.
    PubMed     Abstract available


  101. SMITH JS, Vaz OM, Gaber CE, Des Marais AC, et al
    Recruitment strategies and HPV self-collection return rates for under-screened women for cervical cancer prevention.
    PLoS One. 2023;18:e0280638.
    PubMed     Abstract available


  102. TAKADA A, Yokota H, Nemoto MW, Horikoshi T, et al
    Prognosis prediction of uterine cervical cancer using changes in the histogram and texture features of apparent diffusion coefficient during definitive chemoradiotherapy.
    PLoS One. 2023;18:e0282710.
    PubMed     Abstract available


  103. PAKEN J, Govender CD, Pillay M, Feyasa M, et al
    Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
    PLoS One. 2023;18:e0283639.
    PubMed     Abstract available


  104. LIVESEY M, Rossouw SC, Blignaut R, Christoffels A, et al
    Transforming RNA-Seq gene expression to track cancer progression in the multi-stage early to advanced-stage cancer development.
    PLoS One. 2023;18:e0284458.
    PubMed     Abstract available



  105. Expression of Concern: Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.
    PLoS One. 2023;18:e0285579.
    PubMed    


  106. HOLOPAINEN E, Lahtinen O, Kononen M, Anttila M, et al
    Greater increases in intratumoral apparent diffusion coefficients after chemoradiotherapy predict better overall survival of patients with cervical cancer.
    PLoS One. 2023;18:e0285786.
    PubMed     Abstract available


  107. OKAFOR IP, Kukoyi FO, Kanma-Okafor OJ, Izuka MO, et al
    Male involvement in female partners' screening for breast and cervical cancers in Southwest Nigeria.
    PLoS One. 2023;18:e0284141.
    PubMed     Abstract available


  108. MITI S, Shato T, Asante C, Baumann A, et al
    Leveraging health infrastructure to optimize HPV vaccination for adolescents in Zambia: Protocol for an implementation study.
    PLoS One. 2023;18:e0285031.
    PubMed     Abstract available


  109. KHOMPHAIBOONKIJ U, Sreamsukcharoenchai N, Pitakkarnkul S, Rittiluechai K, et al
    Knowledge of Thai women in cervical cancer etiology and screening.
    PLoS One. 2023;18:e0286011.
    PubMed     Abstract available


  110. KURITA Y, Meguro S, Tsuyama N, Kosugi I, et al
    Accurate deep learning model using semi-supervised learning and Noisy Student for cervical cancer screening in low magnification images.
    PLoS One. 2023;18:e0285996.
    PubMed     Abstract available


  111. PANERU B, Karmacharya A, Bharati A, Makaju S, et al
    Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal.
    PLoS One. 2023;18:e0285771.
    PubMed     Abstract available


  112. JEMAL Z, Chea N, Hasen H, Tesfaye T, et al
    Cervical cancer screening utilization and associated factors among female health workers in public health facilities of Hossana town, southern Ethiopia: A mixed method approach.
    PLoS One. 2023;18:e0286262.
    PubMed     Abstract available


  113. MWENDA V, Bor JP, Nyangasi M, Njeru J, et al
    Integrating human papillomavirus testing as a point-of care service using GeneXpert platforms: Findings and lessons from a Kenyan pilot study (2019-2020).
    PLoS One. 2023;18:e0286202.
    PubMed     Abstract available


  114. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
    Acceptability of self-sampling human papillomavirus test for cervical cancer screening in Japan: A questionnaire survey in the ACCESS trial.
    PLoS One. 2023;18:e0286909.
    PubMed     Abstract available


  115. ALAM Z, Cairns JM, Scott M, Dean JA, et al
    Interventions to increase cervical screening uptake among immigrant women: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0281976.
    PubMed     Abstract available


  116. VAINER G, Huang L, Emancipator K, Nuti S, et al
    Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    PLoS One. 2023;18:e0285764.
    PubMed     Abstract available


  117. JONSDOTTIR B, Wikman A, Sundstrom Poromaa I, Stalberg K, et al
    Advanced gynecological cancer: Quality of life one year after diagnosis.
    PLoS One. 2023;18:e0287562.
    PubMed     Abstract available


  118. STRBAC M, Vukovic V, Pustahija T, Nikolic N, et al
    Motives and attitudes of parents toward HPV vaccination: Results from the initial period of HPV vaccine rollout in Serbia.
    PLoS One. 2023;18:e0287295.
    PubMed     Abstract available


  119. WULANDARI D, Meidyandra RW, Andrijono
    Genotype profiles of high-risk human papillomavirus in women of reproductive age: A community-based study.
    PLoS One. 2023;18:e0287399.
    PubMed     Abstract available


  120. MAHAJAN H, Reddy N, Devi NGM, Poli UR, et al
    Projected cancer burden, challenges, and barriers to cancer prevention and control activities in the state of Telangana.
    PLoS One. 2023;18:e0278357.
    PubMed     Abstract available


  121. FAZLOLLAHPOUR-NAGHIBI A, Bagheri K, Almukhtar M, Taha SR, et al
    Trichomonas vaginalis infection and risk of cervical neoplasia: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0288443.
    PubMed     Abstract available


  122. BAS S, Sijben J, Bischoff EWMA, Bekkers RLM, et al
    Acceptability of risk-based triage in cervical cancer screening: A focus group study.
    PLoS One. 2023;18:e0289647.
    PubMed     Abstract available


  123. CONTRERAS NE, Roldan JS, Castillo DS
    Novel competitive enzyme-linked immunosorbent assay for the detection of the high-risk Human Papillomavirus 18 E6 oncoprotein.
    PLoS One. 2023;18:e0290088.
    PubMed     Abstract available


  124. CHONA EZ, Msengi EA, Gosse RA, Ambikile JS, et al
    The lived experiences and caring needs of women diagnosed with cervical cancer: A qualitative study in Dar es Salaam, Tanzania.
    PLoS One. 2023;18:e0289925.
    PubMed     Abstract available


  125. OKYERE ASANTE PG, Owusu AY, Oppong JR, Amegah KE, et al
    The psychosocial burden of women seeking treatment for breast and cervical cancers in Ghana's major cancer hospitals.
    PLoS One. 2023;18:e0289055.
    PubMed     Abstract available


  126. GONG M, Shen F, Li Y, Ming L, et al
    MLK4 as an immune marker and its correlation with immune infiltration in Cervical squamous cell carcinoma and endocervical adenocarcinoma(CESC).
    PLoS One. 2023;18:e0290462.
    PubMed     Abstract available


  127. URQUHART G, Maclennan SJ, Guntupalli AM
    Is there an association between intimate partner violence and the prevalence of cervical cancer screening in Jordan?
    PLoS One. 2023;18:e0290678.
    PubMed     Abstract available


  128. SUNDARA RAJAN R S, Thomas J, Francis D, Daniel EC, et al
    Effective gene delivery using size dependant nano core-shell in human cervical cancer cell lines by magnetofection.
    PLoS One. 2023;18:e0289731.
    PubMed     Abstract available


  129. ODEH HI, Al-Badi SR, Karima B, Saeed TA, et al
    Exploring the prevalence of Human Papillomavirus (HPV) genotypes in PAP smear samples of women in northern region of United Arab Emirates (UAE): HPV Direct Flow CHIP system-based pilot study.
    PLoS One. 2023;18:e0286889.
    PubMed     Abstract available


  130. WANG S, Wang Y, Zhuang J, Wu Y, et al
    Prognostic significance of index (LANR) composed of preoperative lymphocytes, albumin, and neutrophils in patients with stage IB-IIA cervical cancer.
    PLoS One. 2023;18:e0290905.
    PubMed     Abstract available


  131. MANTULA F, Toefy Y
    Women and health providers' perspectives on male support for cervical cancer screening in Gwanda district, Zimbabwe.
    PLoS One. 2023;18:e0282931.
    PubMed     Abstract available


  132. IORDANISHVILI S, Metreveli T, Lipartia E, Gachechiladze K, et al
    The HPV-TP53-MALAT1 Axis: Unravelling interactions in cervical cancer development.
    PLoS One. 2023;18:e0291725.
    PubMed     Abstract available


  133. FERREIRA HNC, Capistrano GN, Morais TNB, Costa KTDS, et al
    Screening and hospitalization of breast and cervical cancer in Brazil from 2010 to 2022: A time-series study.
    PLoS One. 2023;18:e0278011.
    PubMed     Abstract available


  134. QAQISH A, Abdo N, Abbas MM, Saadeh N, et al
    Awareness and knowledge of physicians and residents on the non-sexual routes of human papilloma virus (HPV) infection and their perspectives on anti-HPV vaccination in Jordan.
    PLoS One. 2023;18:e0291643.
    PubMed     Abstract available


  135. ZHAO X, Gopalappa C
    Joint modeling HIV and HPV using a new hybrid agent-based network and compartmental simulation technique.
    PLoS One. 2023;18:e0288141.
    PubMed     Abstract available


  136. DESTA M, Getaneh T, Yeserah B, Worku Y, et al
    Correction: Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0294799.
    PubMed     Abstract available


  137. TACHIWENYIKA E, Dhodho M, Muchedzi A, Sibanda TP, et al
    Prevalence of Cervical Cancer and Clinical Management of Women Screened positive using visual inspection with acetic acid and Cervicography in selected public sector health facilities of Manicaland and Midlands provinces of Zimbabwe, 2021.
    PLoS One. 2023;18:e0294115.
    PubMed     Abstract available


  138. MAHUMUD RA, Alam K, Dunn J, Gow J, et al
    Correction: The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    PLoS One. 2023;18:e0295688.
    PubMed     Abstract available


  139. QULU W, Mtshali A, Osman F, Ndlela N, et al
    High-risk human papillomavirus prevalence among South African women diagnosed with other STIs and BV.
    PLoS One. 2023;18:e0294698.
    PubMed     Abstract available


  140. ALMASOUDI HH, Nahari MH, Alhazmi AYM, Almasabi SHA, et al
    Delineating Pixantrone Maleate's adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation.
    PLoS One. 2023;18:e0295714.
    PubMed     Abstract available


  141. RAZZAK MA, Islam MN, Aadeeb MS, Tasnim T, et al
    Digital health interventions for cervical cancer care: A systematic review and future research opportunities.
    PLoS One. 2023;18:e0296015.
    PubMed     Abstract available


  142. AL-OSEELY S, Abdul Manaf R, Ismail S
    Factors affecting cervical cancer screening among Yemeni immigrant women in Klang Valley, Malaysia: A cross sectional study.
    PLoS One. 2023;18:e0290152.
    PubMed     Abstract available


  143. GEBREMESKEL TG, Gebretatios MZ
    Determinants of cervical cancer screening utilization among HIV-positive women, in public general hospitals of Central Zone, Tigray, Ethiopia, 2020: Case-control study.
    PLoS One. 2023;18:e0289042.
    PubMed     Abstract available


  144. NOVAIS IR, Coelho CO, Machado HC, Surita F, et al
    Cervical cancer screening in Brazilian Amazon Indigenous women: Towards the intensification of public policies for prevention.
    PLoS One. 2023;18:e0294956.
    PubMed     Abstract available


  145. TOSADO-RODRIGUEZ E, Mendez LB, Espino AM, Dorta-Estremera S, et al
    Inflammatory cytokines and a diverse cervicovaginal microbiota associate with cervical dysplasia in a cohort of Hispanics living in Puerto Rico.
    PLoS One. 2023;18:e0284673.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.